MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx® for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.
"Miraca Life Sciences has established its impeccable reputation on the ability to deliver timely, accurate and actionable diagnoses to clinicians and their patients. Delivering the right answer is largely based upon the quality of available medical information," said Dr. Frank Basile, President and CEO of MLS. "Through this strategic partnership with MDxHealth, we can now offer a well-validated epigenetic assay, which delivers new molecular insights on a patient's risk for undetected cancer, thereby enabling our clients make more informed decisions about the need for a repeat prostate biopsy."
"We are very excited about our strategic partnership with Miraca Life Sciences which provides Miraca's clinicians and their patients with access to ConfirmMDx, and allows us to support their efforts to deliver the highest quality patient care," said Dr. Jan Groen, CEO of MDxHealth. "Miraca Life Sciences is an excellent partner given their services extend across a variety of medical specialties, potentially opening new channels for additional tests currently in our product pipeline."